广州医药 ›› 2016, Vol. 47 ›› Issue (5): 28-30.DOI: 10.3969/j.issn.1000-8535.2016.05.010

• 论著 • 上一篇    下一篇

双歧三联活菌联合补中益气丸治疗腹腔镜胆囊切除术后腹泻临床观察

彭逸潮   

  1. 广东省普宁市人民医院普外区(普宁 515300)
  • 收稿日期:2016-04-11 出版日期:2016-09-20 发布日期:2021-12-02

Clinical observation of the effect on bifid triple viable combined with buzhongyiqi pills in patients with diarrhea after laparoscopic cholecystectomy

Peng Yichao   

  1. Department of General Surgery, The People's Hospital of Puning City, Puning 515300, China
  • Received:2016-04-11 Online:2016-09-20 Published:2021-12-02

摘要: 目的 探讨双歧三联活菌联合补中益气丸治疗腹腔镜胆囊切除术后腹泻患者的临床疗效及安全性。方法 将2014年3月—2015年3月我院收治的68例腹腔镜胆囊切除术后腹泻患者随机分成观察组和对照组(每组34例),观察组患者给予双歧三联活菌联合补中益气丸治疗,对照组患者给予双歧三联活菌治疗,比较两组患者治疗前后的临床症状积分,总体临床疗效以及不良反应。结果 治疗4周后,观察组和对照组患者大便次数、大便性状积分和腹痛/腹部不适积分均明显低于治疗前(P<0.05),同时观察组患者大便次数、大便性状积分和腹痛/腹部不适积分低于对照组患者(P<0.05);观察组和对照组患者临床症状总积分均低于治疗前(P<0.05),且观察组患者临床症状总积分低于对照组患者(P<0.05);观察组患者临床疗效总有效率(91.2%)高于对照组患者临床疗效总有效率为(70.6%)(P=0.03);观察组和对照组患者治疗期间均未出现明显药物不良反应。结论 双歧三联活菌联合补中益气丸治疗腹腔镜胆囊切除术后腹泻能明显改善患者的临床症状,总体疗效较好,不良反应率较低,值得在临床上推广应用。

关键词: 双歧三联活菌, 补中益气丸, 腹腔镜胆囊切除术, 腹泻

Abstract: Objective To investigate the clinical efficacy and safety of bifid triple viable combined with buzhongyiqi pills in treatment of patients with diarrhea after Laparoscopic cholecystectomy. Methods 68 patients with diarrhea after Laparoscopic cholecystectomy in our hospital between March 2014 and March 2015 were randomly divided into observation group and control group with each 34 cases. The patients in observation group were given bifid triple viable and Buzhongyiqi pills therapy and the patients in control group were given bifid triple viable therapy. The clinical symptoms, clinical efficacy and adverse reactions were observed before and after treatment and were compared between two groups. Results After 4 weeks of treatment, the frequency of excrement, scores of excrement consistency and scores of abdominal pain and abdominal unwell in the observation group and the control group were significantly lower than those in relevant groups before treatment (P<0.05) and the frequency of excrement, scores of excrement consistency and scores of abdominal pain and abdominal unwell in observation group were significantly lower than that in the control group (P<0.05). The aggregate score of clinical symptoms in observation group and control group were both significantly lower than that in each group before treatment (P<0.05), and the aggregate score of clinical symptoms in observation group patients was significantly lower than that in the control group patients (P<0.05). The total clinical effective rate in observation group(91.2%)was significantly higher than that in control group(70.6%)(P=0.03). There were no adverse drug reactions in the observation group and the control group during treatment period. Conclusion Bifid triple viable combined with Buzhongyiqi pills in treatment of patients with diarrhea after laparoscopic cholecystectomy could significantly improve clinical symptoms and get good overall effect, which is worthy of clinical application.

Key words: Bifid triple viable, Buzhongyiqi Pills, Laparoscopic cholecystectomy, Diarrhea